MedTrace Logo

To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

NCT06646354 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2025-05-22

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Conditions

Interventions

DRUG

Ezetimibe/Rosuvastatin/Candesartan/Amlodipine

PO, QD, 8 weeks

DRUG

Candesartan/Amlodipine

PO, QD, 8 weeks

DRUG

Candesartan/Rosuvastatin/Ezetimibe

PO, QD, 8 weeks

Sponsors & Collaborators

  • Hyundai Pharm

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-22
Primary Completion
2025-05-19
Completion
2028-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646354 on ClinicalTrials.gov